{
  "ticker": "AT1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973769",
  "id": "02973769",
  "pages": 12,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0949",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7xtcd497djg.pdf",
  "summary": "### **Atomo Diagnostics Limited \u2013 Quarterly Report (Appendix 4C) \u2013 Key Material Information**  \n\n**Operational/Financial Highlights:**  \n- **Revenue**: $1.07m (unaudited) for Q4 FY25; full-year revenue + grant income ~$4.2m (up 2.7% YoY).  \n- **Cash balance**: $3.2m at quarter-end (post-capital raising).  \n- **Capital raised**: ~$2.6m (placement + SPP), net debt-free position.  \n- **Key agreements**:  \n  - Lumos Diagnostics secured 6-year U.S. distribution deal for Pascal FebriDx\u00ae (potential $486m AUD revenue over term).  \n  - HIV self-test orders worth ~$680k from Australian public health programs (FY25 sales: $1.4m, +143% YoY).  \n- **R&D progress**:  \n  - Active Syphilis test shows improved specificity vs. competitors; CLIA waiver study for Pascal FebriDx\u00ae expected completion August 2025.  \n  - Florey clip-in test device development completed, generating commercial interest.  \n\n**Cash Flow (A$'000):**  \n- **Operating cash outflow**: ($323k) for Q4; ($1.95m) YoY.  \n- **Customer receipts**: $1.04m (Q4), $4.76m (FY25).  \n- **Grant funding**: $485k received (CRC-P syphilis project).  \n\n**Board Changes**:  \n- Two new directors appointed (IVD/POC diagnostics expertise); board downsized.  \n\n*Note: Excludes non-material operational commentary and forward-looking statements.*",
  "usage": {
    "prompt_tokens": 5789,
    "completion_tokens": 356,
    "total_tokens": 6145,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:54:20.051983"
}